What were the main drivers of Schering-Plough's revenue growth in Q1 2007?

Revenue growth was driven by a 17% increase in consolidated net sales to $3.0 billion. Key contributors included the Prescription Pharmaceuticals segment, with strong performance from the cholesterol franchise (VYTORIN and ZETIA) managed via a joint venture, and sales growth in products such as REMICADE, NASONEX, TEMODAR, CLARINEX, and AVELOX. The Consumer Health Care and Animal Health segments also saw increases in sales.

What is the significance of the proposed Organon BioSciences acquisition?

The proposed acquisition of Organon BioSciences for approximately 11.0 billion Euros is a significant strategic move aimed at furthering Schering-Plough's value creation strategy. It represents a major step in expanding the company's business and market presence, with an expectation of being accretive to earnings per share in the first full year and achieving substantial synergies over three years.

What are the key financial impacts of the company's legal and regulatory matters?

The company made a significant payment of $379 million in the first quarter of 2007 related to the settlement of the Massachusetts Investigation, which negatively impacted operating cash flow. Schering-Plough also continues to manage other legal and regulatory issues, including an FDA Consent Decree and various investigations, which could potentially lead to fines, penalties, or operational restrictions, impacting future financial performance. The adoption of FIN 48 resulted in a $259 million reduction to retained earnings.

How is the cholesterol joint venture with Merck impacting Schering-Plough's financials?

The cholesterol joint venture, which includes products like VYTORIN and ZETIA, is a critical contributor to Schering-Plough's financial results. While sales of these products are accounted for under the equity method and not included in Schering-Plough's net sales, the company recognized $487 million in equity income from this venture in Q1 2007, a significant increase from $311 million in Q1 2006. This reflects the strong market performance of these key cholesterol-lowering medications.

MRK 10-Q Quarterly Report Q1 FY2007 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation (SP) reported a strong first quarter for 2007, with net sales increasing by 17% to $3.0 billion and net income available to common shareholders reaching $543 million, up from $350 million in the prior year period. This growth was primarily driven by strong performance in its Prescription Pharmaceuticals segment, notably the cholesterol franchise (VYTORIN and ZETIA) through its joint venture with Merck, as well as increased sales of key products like REMICADE and NASONEX. The company also announced a significant strategic move with the proposed acquisition of Organon BioSciences for approximately 11.0 billion Euros, signaling a focus on future growth and value creation. Despite the positive sales and earnings momentum, the company's operating cash flow turned negative due to significant payments related to legal settlements, including the Massachusetts Investigation, and upfront payments for licensing agreements. Schering-Plough continues to manage various legal and regulatory matters, including the ongoing FDA Consent Decree and various investigations. Investors should monitor the progress of the Organon BioSciences acquisition and the resolution of ongoing legal and regulatory challenges, as these will be key factors influencing future financial performance.

Key Highlights

1Net sales increased by 17% to $3.0 billion for the first quarter of 2007, compared to $2.55 billion in the prior year period.
2Net income available to common shareholders rose significantly to $543 million ($0.36 per diluted share) from $350 million ($0.24 per diluted share) in Q1 2006.
3The company announced a proposed acquisition of Organon BioSciences for approximately 11.0 billion Euros, indicating a major strategic growth initiative.
4Equity income from the cholesterol joint venture (VYTORIN and ZETIA with Merck) increased by 56.5% to $487 million, reflecting strong performance of these products.
5Research and Development (R&D) expenses increased by 47% to $707 million, driven by licensing payments and clinical trial activities.
6Operating activities generated negative cash flow of $248 million, primarily due to a $379 million settlement payment for the Massachusetts Investigation and a $130 million currency option purchase for the proposed acquisition.

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2007

Summary

Key Highlights

Frequently Asked Questions